Calculate your SIP ReturnsExplore

|

O H L VOL


Days Range

About Pharmaids Pharmaceuticals

Pharmaids Pharmaceuticals Ltd is a public limited company incorporated on 01st March 1989. The Company is primarily engaged in business of manufacturing of bulk drugs in various forms like tablets, capsules, liquids and powders etc., in allopathic and herbal Ayurvedic and Natural drug formulation. In FY19, the proposed Scheme of Amalgamation of M/s. Emergent Bio Naturals Ltd (Transferor Company) into M/s. Pharmaids Pharmaceuticals Ltd (Transferee Company) pursuant to section 230 to 232 of the Companies Act, 2013 is pending for approval before the NCLT, Hyderabad Bench.

Parent Organisation
Indian Private
Managing Director
Shankarappa Nagaraja Vinaya Babu
Founded
1989
NSE Symbol

Peer Comparision

StocksMarket Cap (cr)Market Price (₹)52 Week Low-High (₹)

Pharmaids Pharmaceuticals Ltd FAQs

Pharmaids Pharmaceuticals Ltd (Pharmaids Pharmaceuticals Ltd) share price as of May 30, 2024, on NSE is Rs 2,851.15 (NSE) and Rs 2,860.00 (BSE) on BSE.
Yes, You can buy Pharmaids Pharmaceuticals Ltd (Pharmaids Pharmaceuticals Ltd) shares by opening a Demat account with Angel One.
Pharmaids Pharmaceuticals Ltd (Pharmaids Pharmaceuticals Ltd) share can be bought through the following modes:
1. Direct investment: You can buy Pharmaids Pharmaceuticals Ltd (Pharmaids Pharmaceuticals Ltd) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Pharmaids Pharmaceuticals Ltd (Pharmaids Pharmaceuticals Ltd) shares.
Open Free Demat Account!

Enjoy Zero Brokerage on Equity Delivery

Join our 2 Cr+ happy customers

+91
Top Stocks

VIEW ALLView All Stocks

Top Gainers

    VIEW ALLView All Stocks

    Top Losers

      VIEW ALLView All Stocks

      Enjoy Zero Brokerage on Equity Delivery
      4.4 Cr+DOWNLOADS
      Enjoy Zero Brokerage on Equity Delivery

      Get the link to download the App

      Send App Link

      Enjoy Zero Brokerage on
      Equity Delivery